Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been given a consensus recommendation of “Moderate Buy” by the eight ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $7.8571.

GANX has been the topic of a number of analyst reports. BTIG Research reissued a “buy” rating and issued a $9.00 price target on shares of Gain Therapeutics in a research note on Wednesday. Weiss Ratings reissued a “sell (e+)” rating on shares of Gain Therapeutics in a research note on Wednesday, October 8th. Roth Capital cut their price target on Gain Therapeutics from $7.00 to $6.00 and set a “buy” rating on the stock in a research note on Wednesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, October 13th. Finally, Maxim Group increased their price target on Gain Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, October 7th.

Institutional Trading of Gain Therapeutics

Large investors have recently made changes to their positions in the company. Kovitz Investment Group Partners LLC bought a new stake in shares of Gain Therapeutics in the 1st quarter valued at $91,000. Dauntless Investment Group LLC bought a new stake in shares of Gain Therapeutics in the 1st quarter valued at $240,000. Marshall Wace LLP increased its position in shares of Gain Therapeutics by 41.0% in the 2nd quarter. Marshall Wace LLP now owns 276,433 shares of the company’s stock valued at $498,000 after buying an additional 80,407 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Gain Therapeutics by 2.9% in the 2nd quarter. Geode Capital Management LLC now owns 290,462 shares of the company’s stock valued at $523,000 after buying an additional 8,251 shares in the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Stock Up 3.3%

NASDAQ:GANX opened at $1.87 on Friday. The stock’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.78. Gain Therapeutics has a 52-week low of $1.41 and a 52-week high of $2.90. The company has a debt-to-equity ratio of 0.09, a quick ratio of 1.79 and a current ratio of 1.79. The company has a market cap of $67.23 million, a price-to-earnings ratio of -2.97 and a beta of 0.11.

Gain Therapeutics (NASDAQ:GANX) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.02). On average, analysts anticipate that Gain Therapeutics will post -1 EPS for the current year.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.